Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
Status:
Completed
Trial end date:
2016-05-17
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well giving bortezomib with or without combination
chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma
who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
cyclophosphamide, dexamethasone, and lenalidomide, work in different ways to stop the growth
of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet
known whether giving bortezomib is more effective with or without combination chemotherapy in
the post transplant setting.